Is there an Indian generic version of Lorlatinib?

Lorlatinib (Lorlatinib) is mainly used to treat ALK (tyrosine kinase) and ROS1 positive patients in non-small cell lung cancer (NSCLC). The main effect of lorlatinib is to inhibit the activity of the two fusion genes ALK and ROS1. Mutations in these genes play a key role in some patients with NSCLC, causing abnormal proliferation and spread of tumor cells. Lorlatinib effectively controls the growth of cancer cells by targeting these abnormal signaling pathways.

There are currently no generic drugs of Lorlatinib officially marketed in India. Lorlatinib has been launched in China and is included in medical insurance. Patients can purchase it domestically, but the price is relatively high, about 10,000 to 20,000 yuan. For details, please consult the local hospital pharmacy. There are original drugs and cheaper generic drugs abroad. The cheaper ones are the original drugs from Turkey, which cost more than 1,000 yuan, and the original drugs from Hong Kong, China, which cost about 30,000 yuan. Generic drugs are mainly generic drugs from Laos and Bangladesh. The price is about several thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.

Lorlatinib is a highly targeted drug that specifically acts on ALK and ROS1 positive tumor cells, minimizing unnecessary interference with healthy cells. Lorlatinib is multi-targeting, meaning it can address some mutations that confer resistance to other ALK inhibitors, providing new treatment options for patients who have previously developed resistance to other treatments.

Although lorlatinib is a targeted drug, it may still be accompanied by some side effects during use, such as fatigue, shortness of breath, nausea, headache, etc. These side effects require close monitoring and management during treatment.